SCIENTIFIC PUBLICATIONS AND POSTERS
Home » Resources / Publications and Posters
Poster: 40HZ-Auditory Steady-State-Response as a New Tool for Drug Discovery in Schizophrenia
In this Poster, we took advantage of quantitative electroencephalography (qEEG) and related methodologies (auditory evoked potentials) to characterize a humanized rat model of Fragile X.
Poster: EEG Phenotyping as a Loop Translation Tool to Address the Pathophysiology of GABA-A Signaling-associated Brain Disorders
In this Poster, we took advantage of quantitative electroencephalography (qEEG) and related methodologies (auditory evoked potentials) to characterize a humanized rat model of Fragile X.
Poster: Alteration in Spontaneous and Auditory Evoked Electrophysiological Activities in a Rat Model of Fragile X Syndrome
In this Poster, we took advantage of quantitative electroencephalography (qEEG) and related methodologies (auditory evoked potentials) to characterize a humanized rat model of Fragile X.
Poster: Identification of Specific EEG Biomarkers in Aged Mice
This new analysis pipeline provides a tool to more quickly and objectively assess the effects of compounds in development and compare them to existing reference drugs for various indications.
Poster: Standardized Pharmaco-Sleep-Electroencephalography as a Preclinical Tool for Antidepressant Drug Profiling
We evaluated the possibility to employ a Machine Learning approach to assess the dose-dependency of antidepressants, with distinct mechanisms of action: fluoxetine and maprotiline in wild-type C57BL/6 mice.
Poster: Assessing Sleep Architecture and Pharmacodynamics: An EEG-Based Platform for Drug Testing
This new analysis pipeline provides a tool to more quickly and objectively assess the effects of compounds in development and compare them to existing reference drugs for various indications.
Poster: Characterization of a Transgenic Mouse Model of Tauopathy Using qEEG
To investigate a translatable model related to tau pathology, we studied changes in EEG characteristics with age in the P301L tauopathy mouse model.
Publication: Pronounced Antiepileptic Activity of the Subtype-Selective GABAA -Positive Allosteric Modulator PF-06372865 in the GAERS Absence Epilepsy Model
Generalized Absence Epilepsy.
A joint publication SynapCell x Pfizer.
Poster: The Use of Quantitative EEG and Phase Amplitude Coupling for the Identification of New Brain Functional Signatures
In this poster, we identify functional signatures in mice using qEEG and related methodologies (Phase Amplitude Coupling and cPAC).
Poster: Decoding Therapeutic Signatures: The Contribution of Pharmaco-EEG in Profiling Compounds with Varied Mechanisms of Action
The goal: Defining the potential specific signature associated with a therapeutic class of compounds.
Poster: Translational Pharmacology in Essential Tremor – Relevance of Electrophysiological Biomarkers
We characterize the effects of compounds with various mechanisms of action in the rat model of Essential Tremor.
Poster: Improving Drug Discovery in Parkinson’s Disease Using Brain Oscillations as Translational Biomarkers
We investigate the use of aberrant cortical oscillations as translational biomarkers for Parkinson’s Disease Drug development and evaluate the effect of acute (L-Dopa, Apomorphine) and …
Poster: Pronounced Antiepileptic Activity of the Subtype-Selective GABAA Positive Alosteric Modulator PF-06372865 in the GAERS Model
Assessing the antiepileptic effect of PF-06372865, a newly developed GABAA modulator, developed by Pfizer, in a preclinical model of absence seizures, the GAERS rat.
Poster: The SynapCell MTLE Model, a Predictive Model of Focal Epilepsy for Drug Discovery
A powerful preclinical tool accelerating drug-resistant epilepsy research. This MTLE model accurately mirrors human focal Epilepsy capturing drug sensitivities and crucial EEG biomarkers.
Poster: Pharmacological Assessment of Anti-Seizure Medications in the Rat Amygdala-Kindling Model
This study intends to highlight translational and predictive aspects of the amygdala-kindling model as a potential asset for characterizing new entities with improved tolerability and efficacy.